

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**ANNOUNCEMENT**

**PRELIMINARY FINANCIAL INFORMATION OF CR SANJIU  
FOR THE YEAR ENDED 31 DECEMBER 2024**

On 10 February 2025, CR Sanjiu released its unaudited preliminary financial information for the year ended 31 December 2024.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”) is a company incorporated in the People’s Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.02% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 10 February 2025, CR Sanjiu released its unaudited preliminary financial information for the year ended 31 December 2024 (the “**Reporting Period**”) (the “**CR Sanjiu Preliminary Financial Information**”). Set out below are the key financial information of the CR Sanjiu Preliminary Financial Information:

**I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2024 (UNAUDITED)**

*Unit: RMB ten thousand*

<b>Item</b>	<b>The Reporting Period</b>	<b>The corresponding period of previous year</b>	<b>Increase (%)</b>
Total operating revenue	2,761,661.18	2,473,896.33	11.63%
Operating profit	447,695.91	375,337.57	19.28%
Total profit	459,553.89	375,445.32	22.40%
Net profit attributable to the shareholders of the listed company	336,934.91	285,293.17	18.10%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	311,514.60	271,098.42	14.91%
Basic earnings per share (RMB)	2.63	2.24	17.41%
Weighted average return on net asset (%)	17.34%	15.86%	1.48 percentage points

<b>Item</b>	<b>As of the end of the Reporting Period</b>	<b>As of the beginning of the Reporting Period</b>	<b>Increase/decrease (%)</b>
Total assets	4,008,390.02	4,014,845.59	-0.16%
Equity attributable to the shareholders of the listed company	1,990,457.14	1,896,714.19	4.94%
Share capital	128,429.87	98,818.40	29.97%
Net assets per share attributable to the shareholders of the listed company (RMB)	15.50	19.19	-19.23%

*Notes:*

- (1) The above information is based on information from unaudited consolidated financial statements. The financial information set out in the 2024 annual report to be published by CR Sanjiu shall prevail.

- (2) In June 2024, CR Sanjiu completed the implementation of its 2023 profit distribution plan, distributing three new shares for every 10 shares to all of its shareholders using the capital reserve. As of the end of 2024, the net asset value per share attributable to shareholders of the listed company is calculated based on the increased share capital following such distribution.

## II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

In 2024, under complex economic and market conditions, CR Sanjiu anchored its strategic direction, consolidated innovative development synergy, adhered to the dual drivers of “brand + innovation,” continuously built its brand influence, consolidated brand leadership, strengthened the construction of the innovation system, enhanced the capacity for innovation and transformation, promoted mergers and acquisitions integration, integrated high-quality industry resources, strengthened the construction of the industrial chain, and supported the inheritance and development of traditional Chinese medicine. These continuously enhanced its core competitiveness, promoted high-quality development, and promoted the steady advancement towards the strategic goals of striving to become a leading enterprise in the industry and doubling operating income under the 14th Five-Year Plan. During the Reporting Period, CR Sanjiu achieved a total operating income of RMB27.617 billion, representing a year-on-year increase of approximately 11.63%; a total profit of RMB4.596 billion, representing a year-on-year increase of approximately 22.40%; and a net profit attributable to shareholders of the listed company of RMB3.369 billion, representing a year-on-year increase of approximately 18.10%.

The CR Sanjiu Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by CR Sanjiu in its 2024 annual report shall prevail.

The financial information is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Sanjiu audited annual financial results of CR Sanjiu, please refer to the annual report for the year ended 31 December 2024 to be published by CR Sanjiu on the website of the Shenzhen Stock Exchange ([www.szse.cn](http://www.szse.cn)).

By Order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Mr. Bai Xiaosong**  
*Chairman*

PRC, 10 February 2025

*As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*